Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2020-03-24 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific employees and executives, including exercise prices, vesting periods, and valuation methods. Since this is a specific regulatory disclosure regarding capital structure and equity-based compensation that does not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is classified as a Regulatory Filing.
2020-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Optipharm. It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, profit/loss), and details regarding the external auditor. While it contains financial data, it is a specific regulatory disclosure of the audit results rather than a full 10-K annual report or a simple announcement of report publication. Given the focus on the audit opinion and financial statements, it falls under the Audit Report/Information category. FY 2019
2020-03-16 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Optipharm. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2020-03-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 1% confidence The document is a regulatory filing from a Korean company (Optipharm) regarding a significant change in financial structure (30% or more change in revenue or profit/loss). This is a standard disclosure requirement for listed companies in Korea (DART system) to report preliminary financial results before the final audit is completed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the category of an Earnings Release (ER).
2020-03-09 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Optipharm, dated March 9, 2020. It contains the agenda for the meeting, including financial statement approval, director appointments, and remuneration limits. It also includes detailed management information such as board activity reports, audit committee details, and major shareholder transaction disclosures. This document is a standard proxy statement/notice of meeting sent to shareholders to solicit votes and provide information for the upcoming AGM. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification.
2020-03-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is specifically used to report insider trading or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2020-02-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.